🇺🇸 FDA

Intelligence Platform

Patents

Browse 14 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12377106

Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degra

NURIX THERAPEUTICS, INC. · Granted Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12234230

Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

NURIX THERAPEUTICS, INC. · Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12121540

CBL inhibitors and compositions for use in adoptive cell therapy

NURIX THERAPEUTICS, INC. · Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12091426

Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

NURIX THERAPEUTICS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12049471

Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof

NURIX THERAPEUTICS, INC. · Granted Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12016860

Combination therapies with Cbl-b inhibitor compounds

NURIX THERAPEUTICS, INC. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11951133

3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

NURIX THERAPEUTICS, INC. · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866442

Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

NURIX THERAPEUTICS, INC. · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11820781

Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

NURIX THERAPEUTICS, INC. · Granted Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11739101

Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

NURIX THERAPEUTICS, INC. · Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11530229

Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof

NURIX THERAPEUTICS, INC. · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11479556

Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway

NURIX THERAPEUTICS, INC. · Granted Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11464802

3-substituted piperidine compounds for Cbl-b inhibition, and use thereof

NURIX THERAPEUTICS, INC. · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11401267

Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof

NURIX THERAPEUTICS, INC. · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted